No products in the cart.
LGD-4033 gets sold as the smart alternative to testosterone. All the muscle, none of the side effects. That is the pitch. And for some people, it sounds like exactly what they want. But when you put the actual clinical data side by side, the safer SARM story falls apart in several important areas. Here is what the research actually shows when you compare LGD-4033 and testosterone directly.
What LGD-4033 Actually Is
LGD-4033, also called Ligandrol, is a selective androgen receptor modulator. It was developed to target androgen receptors in muscle and bone specifically, while having less effect on organs like the prostate.
It is taken orally, not injected. It was designed to deliver anabolic effects without the androgenic side effects that come with testosterone. That is the theory. The clinical reality is more complicated.
It is not FDA-approved for any use. It is classified as a research compound in the US and UK. WADA bans it in all competitive sport under the S1 Anabolic Agents category, the same category as anabolic steroids.
What the Only Human Trial Actually Found
The foundational Phase 1 clinical trial on LGD-4033 enrolled 76 healthy men and gave them 0.1mg, 0.3mg, or 1.0mg per day for 21 days. This is the most cited piece of evidence for LGD-4033’s safety.
What it found:
- Lean muscle mass increased significantly in a dose-dependent manner
- No serious adverse events at these doses
- No liver toxicity at these doses
- No PSA changes
But also:
- Dose-dependent suppression of total testosterone
- Free testosterone dropped significantly at 1mg per day
- HDL cholesterol dropped
- Triglycerides decreased
- FSH and LH were suppressed
The doses used in this trial were 0.1 to 1mg per day. The doses commonly used in bodybuilding are 5 to 20mg per day. That is 5 to 200 times higher than what was studied.
Testosterone Suppression: How Bad Is It Really?
This is one of the biggest gaps between the “safer SARM” claim and clinical reality.
The Phase 1 trial found that at 1mg per day, total testosterone dropped by 50 percent and free testosterone dropped by approximately 40 percent over just 21 days.
Inside Bodybuilding’s clinical data confirms that after 56 days off LGD-4033, testosterone returned to normal. So recovery happens. But at bodybuilding doses of 10 to 20mg, the suppression is significantly more pronounced and the recovery window is longer.
The claim that LGD-4033 does not suppress testosterone the way steroids do is simply not accurate. It suppresses LH, FSH, and both total and free testosterone. It just does so through a different pathway.
Unlike testosterone, LGD-4033 has no aromatization. This means no estrogen conversion and no need for an aromatase inhibitor. That is a genuine advantage. But the suppression itself is real and needs PCT.
Liver Toxicity: The Risk Nobody Expected
The Phase 1 trial at 0.1 to 1mg showed no liver toxicity. That result contributed heavily to the “safer” narrative.
But multiple published case reports tell a different story at higher doses.
A PMC case report documented a 32-year-old who developed severe drug-induced liver injury after taking 10mg of LGD-4033 daily for just two weeks. Liver biopsy confirmed cholestatic hepatitis with fibrosis. His liver enzymes were dramatically elevated.
A second PMC report (Cureus 2024) documented a 52-year-old who developed jaundice, significant weight loss, and elevated liver enzymes after three months of high-dose LGD-4033. His dose was also 10 to 100 times higher than what was studied in the clinical trial.
Revolution Health confirms: LGD-4033 undergoes hepatic metabolism and liver stress is a legitimate concern, even though it is not 17-alpha-alkylated like oral steroids.
The pattern is clear. At clinical trial doses, liver toxicity was not observed. At the doses people actually use for performance, liver damage cases are documented in peer-reviewed literature.
Cholesterol and Cardiovascular Risk
Both testosterone and LGD-4033 affect cholesterol, but in somewhat different ways.
Testosterone at performance doses lowers HDL and raises LDL. LGD-4033 lowers HDL and triglycerides. Inside Bodybuilding attributes this to hepatic lipase stimulation from oral processing through the liver.
A documented case in Inside Bodybuilding’s clinical records involved a patient who suffered a heart attack after nine months of continuous LGD-4033 use at 30mg per day. The cardiovascular risk from long-term LGD-4033 at high doses is not theoretical.
ScienceInsights is direct: the drug still affects hormonal systems beyond muscle tissue. The cardiovascular risk exists even without estrogen conversion.
Where LGD-4033 Actually Has an Advantage Over Testosterone
Being fair about this matters.
No injection required. Oral dosing removes the infection risk of improper injection technique. For users who struggle with injections this is a genuine practical advantage.
No estrogen conversion. Testosterone aromatizes and requires estrogen management. LGD-4033 does not convert to estrogen. No gynecomastia risk from estrogen. No need for an aromatase inhibitor.
No DHT conversion. Testosterone converts to DHT, which accelerates hair loss and can affect the prostate. LGD-4033 does not convert to DHT.
Potentially easier to manage for beginners. The estrogen and DHT side effect landscape is simpler, which some users find more manageable on a first cycle.
Where Testosterone Is Actually Safer
Decades of human data. Testosterone has been studied and used medically for over 80 years. Its side effects, risks, and recovery patterns are thoroughly understood. LGD-4033 has one Phase 1 trial at very low doses and a growing number of adverse case reports at the doses people actually use.
Predictable liver profile. Injectable testosterone does not require hepatic first-pass metabolism and carries minimal direct liver risk. LGD-4033 goes through the liver orally and liver damage at higher doses is documented.
Recoverable suppression with clear protocols. Testosterone suppression and PCT protocols for testosterone are well established. LGD-4033’s suppression patterns at performance doses are less studied and PCT needs are less defined.
No documented heart attack cases at TRT doses. The myocardial infarction case linked to LGD-4033 at 30mg for nine months has no parallel in the testosterone literature at equivalent medical doses.
LGD-4033 on TRT: Does It Remove the Suppression Risk?
A common question is whether combining LGD-4033 with TRT removes the suppression concern since testosterone is already being provided externally.
The answer is partially. Your exogenous testosterone covers the serum testosterone drop. But LGD-4033 still suppresses LH and FSH, which matters for testicular function and fertility. PUURHW confirms: even on TRT, LGD-4033 causes further suppression of LH and FSH, which can accelerate testicular atrophy and create hormonal imbalances that are difficult to reverse.
The liver and cardiovascular risks apply equally whether you are on TRT or not.
Frequently Asked Questions
Is LGD-4033 actually safer than testosterone? In some ways yes, in others no. LGD-4033 avoids estrogen conversion, DHT conversion, and injection risks. But it carries documented liver damage risk at performance doses, has less human safety data, and its testosterone suppression is real and requires PCT.
Does LGD-4033 suppress testosterone less than steroids? At clinical trial doses of 1mg, yes. At bodybuilding doses of 10 to 20mg, total testosterone drops by 50 percent or more in 21 days. PCT is required after LGD-4033 at performance doses.
Can LGD-4033 damage your liver? Yes, documented cases exist. A 32-year-old developed severe liver injury from 10mg daily for two weeks. The Phase 1 trial showed no liver toxicity at 0.1 to 1mg. The gap between clinical trial doses and real-world doses is where the risk lives.
Do you need PCT after LGD-4033? Yes. Free testosterone dropped 40 percent and total testosterone 50 percent in the Phase 1 trial at just 1mg. At higher performance doses, PCT with Nolvadex or Clomid is standard and not optional.
Conclusion
LGD-4033 is not simply a safer testosterone. It avoids some of testosterone’s specific risks, estrogen conversion, DHT, injections, but creates its own: liver toxicity at performance doses, documented cardiovascular risk with long-term high-dose use, and testosterone suppression that requires PCT. Testosterone has 80 years of human data behind it. LGD-4033 has one Phase 1 trial at doses far below what most users take. The honest answer is that both compounds carry risk and neither is consequence-free.
